Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7246721 | 1.00 | ACHE (0.43) | ACHECHRNB2CHRNA4CHRNA7FDPS | |
| SCHEMBL29422947 | 1.00 | ACHE (0.43) | ACHECHRNB2CHRNA4CHRNA7FDPS | |
| SCHEMBL7246724 | 1.00 | ACHE (0.43) | ACHECHRNB2CHRNA4CHRNA7FDPS | |
| SCHEMBL7240759 | 0.88 | ACHE (0.46) | ACHE | |
| SCHEMBL7240762 | 0.88 | ACHE (0.46) | ACHE | |
| SCHEMBL7240765 | 0.88 | ACHE (0.46) | ACHE | |
| SCHEMBL3819190 | 0.86 | CHRNB2 (0.38) | ACHECHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL52345 | 0.85 | CHRNB2 (0.37) | ACHECHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL3134497 | 0.85 | CHRNB2 (0.37) | ACHECHRNB2CHRNA4CHRNA7 | |
| SCHEMBL4541235 | 0.75 | ACHE (0.39) | ACHECHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003014089-A1 | AMINOTETRAHYDROISOQUINOLINE DERIVATIVES AS ANALGESICS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2003-02-20 | — | — | WO | disclosed |
| US-6503922-B2 | Central nervous system (CNS); bridged nicotine analogs of N-octylnicotinium iodide (NONI) having selective antagonist properties at alpha 3 beta 2-containing nicotinic receptor subtypes | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-01-07 | — | — | US | disclosed |
| US-20020099069-A1 | Bridged nicotine compounds for use in the treatment of CNS pathologies | KENTUCKY RESEARCH FOUNDATION, UNIVERSITY OF | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099069-A1 | Bridged nicotine compounds for use in the treatment of CNS pathologies | CHRNB2, CHRNA5, CHRNA2 | ACHE 94/4885CHRNB2 1/4885CHRNA4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.